Redx Pharma is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high unmet medical need, in cancer and fibrosis. By improving the characteristics of existing drug classes, we aim to create differentiated, novel drugs.
Redx has an established portfolio of proprietary drug programs that it is developing alone and in partnership with leading pharmaceutical companies and healthcare bodies. Our Porcupine inhibitor, RXC004, is advancing into Phase I clinical development for gastric, biliary and pancreatic cancers.
It is our aim that our discoveries will provide a pipeline of potential assets to complement and combine with the drug portfolios of larger and emerging pharmaceutical companies.
Porcupine is a key enzyme in the oncogenic Wnt signalling pathway. This pathway is implicated in a range of hard-to-treat cancers with poor prognosis such as pancreatic, biliary and gastric cancers. Our Porcupine inhibitor, RXC004, is a potent inhibitor of this enzyme and pathway, leading to strong tumour growth inhibitory effects in a variety of cancer models.
We have recently shown that RXC004, when administered together with an immune checkpoint inhibitor (anti-PD-1) has a synergistic immune system modifying effect.
We are also exploring the use of a porcupine inhibitor in a number of fibrotic disease models.
Our Pipeline page provides more information on the programs currently in development.